{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:24:31Z","timestamp":1791015871305,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MSC technical support in writing this manuscript was funded by FAES FARMA"},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>The aim of this review, is to present an updated revision of topical management of SAC and PAC, based on the available scientific evidence and focused on the impact of ophthalmic solution formulations on eye surface.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Physicians treating ocular allergy should be aware of tear film and tear film disruption in SAC and PAC, and how eye drop composition and additives affect the physiology of the allergic eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Seasonal and perennial allergic conjunctivitis (SAC and PAC) are the most frequent causes of ocular allergy (OA), and both conditions are underdiagnosed and undertreated. SAC and PAC are immunoglobulin E (IgE)-mediated hypersensitivity reactions. The additional tear film disruption caused by the release of inflammatory mediators increases and exacerbates the impact of signs and symptoms and may trigger damage of the ocular surface. Comorbidities are frequent, and dry eye disease in particular must be considered. Clinical guidelines for the management of SAC and PAC recommend topical therapy with antihistamines, mast cells stabilizers or dualaction agents as first-line treatment, but care should be taken, as many medications contain other compounds that may contribute to ocular surface damage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11882-024-01150-0","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T04:01:51Z","timestamp":1718251311000},"page":"347-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Allergic Conjunctivitis Management: Update on Ophthalmic Solutions"],"prefix":"10.1007","volume":"24","author":[{"given":"Andrea","family":"Leonardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Quintieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio J\u00e1uregui","family":"Presa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Merayo","family":"LLoves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Ben\u00edtez-del-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier Seoane","family":"Lest\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elo\u00edna","family":"Gonz\u00e1lez-Mancebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Asero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Groblewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"issue":"2","key":"1150_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.anai.2019.11.014","volume":"124","author":"L Bielory","year":"2020","unstructured":"Bielory L, Delgado L, Katelaris CH, Leonardi A, Rosario N, Vichyanoud P. ICON: diagnosis and management of allergic conjunctivitis. Ann Allergy Asthma Immunol. 2020;124(2):118\u201334.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1150_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jtos.2022.08.009","volume":"26","author":"S Bonini","year":"2022","unstructured":"Bonini S, Leonardi A. The multifaceted aspects of ocular allergies: phenotypes and endotypes. Ocul Surf. 2022;26:174\u201383. Reevaluation of ocular allergy classification based on phenotypes and endotypes.","journal-title":"Ocul Surf"},{"issue":"4","key":"1150_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.alit.2022.07.005","volume":"71","author":"D Miyazaki","year":"2022","unstructured":"Miyazaki D, Fukushima A, Uchio E, Shoji J, Namba K, Ebihara N, et al. Executive summary: Japanese guidelines for allergic conjunctival diseases 2021. Allergol Int. 2022;71(4):459\u201371.","journal-title":"Allergol Int"},{"issue":"2","key":"1150_CR4","first-page":"94","volume":"25","author":"MC S\u00e1nchez-Hern\u00e1ndez","year":"2015","unstructured":"S\u00e1nchez-Hern\u00e1ndez MC, Montero J, Rondon C, Del Ben\u00edtez JM, Vel\u00e1zquez E, Herreras JM, et al. Consensus document on allergic conjunctivitis (DECA). J Invest Allergol Clin Immunol. 2015;25(2):94\u2013106.","journal-title":"J Invest Allergol Clin Immunol"},{"key":"1150_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13601-020-00349-4","volume":"10","author":"MC Sanchez-Hernandez","year":"2020","unstructured":"Sanchez-Hernandez MC, Navarro AM, Colas C, Del Cuvillo A, Sastre J, Mullol J, et al. Validation of the DECA criteria for allergic conjunctivitis severity and control. Clin Transl Allergy. 2020;10:43.","journal-title":"Clin Transl Allergy"},{"issue":"4","key":"1150_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.alit.2020.06.004","volume":"69","author":"D Miyazaki","year":"2020","unstructured":"Miyazaki D, Fukagawa K, Okamoto S, Fukushima A, Uchio E, Ebihara N, et al. Epidemiological aspects of allergic conjunctivitis. Allergol Int. 2020;69(4):487\u201395.","journal-title":"Allergol Int"},{"key":"1150_CR7","doi-asserted-by":"crossref","unstructured":"Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16(1).","DOI":"10.1186\/s13223-020-0403-9"},{"issue":"5","key":"1150_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/all.15174","volume":"77","author":"N Singh","year":"2022","unstructured":"Singh N, Diebold Y, Sahu SK, Leonardi A. Epithelial barrier dysfunction in ocular allergy. Allergy. 2022;77(5):1360\u201372.","journal-title":"Allergy"},{"issue":"5","key":"1150_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/ACI.0b013e32834a95c9","volume":"11","author":"F Mantelli","year":"2011","unstructured":"Mantelli F, Tranchina L, Lambiase A, Bonini S. Ocular surface damage by ophthalmic compounds. Curr Opin Allergy Clin Immunol. 2011;11(5):464\u201370.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"1150_CR10","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1080\/09273948.2020.1841804","volume":"29","author":"A Leonardi","year":"2021","unstructured":"Leonardi A, Modugno RL, Salami E. Allergy and Dry Eye Disease. Ocul Immunol Inflamm. 2021;29(6):1168\u201376. Ocular allergy and dry eye have different pathophysiology but may share common symptoms and may overlap in the same patient.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"1150_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/DER.0000000000000160","volume":"27","author":"AB Wentworth","year":"2016","unstructured":"Wentworth AB, Yiannias JA, Davis MD, Killian JM. Benzalkonium Chloride: a known irritant and Novel Allergen. Dermatitis. 2016;27(1):14\u201320.","journal-title":"Dermatitis"},{"issue":"1","key":"1150_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/mi.2012.44","volume":"6","author":"JG Galletti","year":"2013","unstructured":"Galletti JG, Gabelloni ML, Morande PE, Sabbione F, Vermeulen ME, Trevani AS, et al. Benzalkonium chloride breaks down conjunctival immunological tolerance in a murine model. Mucosal Immunol. 2013;6(1):24\u201334.","journal-title":"Mucosal Immunol"},{"issue":"9","key":"1150_CR13","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1167\/iovs.14-14075","volume":"55","author":"M Guzm\u00e1n","year":"2014","unstructured":"Guzm\u00e1n M, Sabbione F, Gabelloni ML, Vanzulli S, Trevani AS, Giordano MN, et al. Restoring conjunctival tolerance by topical nuclear factor-\u03baB inhibitors reduces preservative-facilitated allergic conjunctivitis in mice. Invest Ophthalmol Vis Sci. 2014;55(9):6116\u201326.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1150_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41572-020-00227-0","volume":"6","author":"J Bousquet","year":"2020","unstructured":"Bousquet J, Anto JM, Bachert C, Baiardini I, Bosnic-Anticevich S, Walter Canonica G, et al. Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):95.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1150_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5114\/pdia.2016.63942","volume":"33","author":"P Kuna","year":"2016","unstructured":"Kuna P, Jurkiewicz D, Czarnecka-Operacz MM, Pawliczak R, Woro\u0144 J, Moniuszko M, et al. The role and choice criteria of antihistamines in allergy management - expert opinion. Postepy Dermatol Alergol. 2016;33(6):397\u2013410.","journal-title":"Postepy Dermatol Alergol"},{"issue":"5","key":"1150_CR16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/ACI.0000000000000563","volume":"19","author":"A Leonardi","year":"2019","unstructured":"Leonardi A, Borghesan F, Scalora T, Modugno RL, Bonaldo A. Office-based ocular procedures for the allergist. Curr Opin Allergy Clin Immunol. 2019;19(5):488\u201394.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"9","key":"1150_CR17","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/all.13786","volume":"74","author":"A Leonardi","year":"2019","unstructured":"Leonardi A, Silva D, Perez Formigo D, Bozkurt B, Sharma V, Allegri P, et al. Management of ocular allergy. Allergy. 2019;74(9):1611\u201330.","journal-title":"Allergy"},{"issue":"2","key":"1150_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/112067211002000201","volume":"20","author":"J Palmares","year":"2010","unstructured":"Palmares J, Delgado L, Cidade M, Quadrado MJ, Filipe HP. Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life. Eur J Ophthalmol. 2010;20(2):257\u201364.","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"1150_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/all.13317","volume":"73","author":"G Roberts","year":"2018","unstructured":"Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, van Gerth R, et al. EAACI guidelines on Allergen Immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765\u201398.","journal-title":"Allergy"},{"issue":"6","key":"1150_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2500\/aap.2020.41.200068","volume":"41","author":"L Bielory","year":"2020","unstructured":"Bielory L. Allergic inflammation of the anterior surface of the eye. Allergy Asthma Proc. 2020;41(6):449\u201353.","journal-title":"Allergy Asthma Proc."},{"issue":"5","key":"1150_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/cod.13209","volume":"80","author":"L Gilissen","year":"2019","unstructured":"Gilissen L, De Decker L, Hulshagen T, Goossens A. Allergic contact dermatitis caused by topical ophthalmic medications: keep an eye on it! Contact Dermat. 2019;80(5):291\u20137.","journal-title":"Contact Dermat"},{"issue":"2","key":"1150_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/09273948.2018.1560478","volume":"28","author":"KG Boboridis","year":"2020","unstructured":"Boboridis KG, Kozeis N, Konstas AG. Revisiting Ocular Allergy: evaluating symptoms, Benzalkonium Chloride and Efficacy of Topical Ketotifen 0.025. Ocul Immunol Inflamm. 2020;28(2):188\u201390.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"1150_CR23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.clinthera.2007.03.017","volume":"29","author":"GW Ousler 3rd","year":"2007","unstructured":"Ousler GW 3rd, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther. 2007;29(4):611\u20136.","journal-title":"Clin Ther"},{"issue":"1","key":"1150_CR24","first-page":"65","volume":"1","author":"J Gane","year":"2013","unstructured":"Gane J, Buckley R. Leukotriene receptor antagonists in Allergic Eye Disease: a systematic review and Meta-analysis. J Allergy Clin Immunology: Pract. 2013;1(1):65\u201374.","journal-title":"J Allergy Clin Immunology: Pract"},{"issue":"6","key":"1150_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.18176\/jiaci.0960","volume":"33","author":"J Montero-Iruzubieta","year":"2023","unstructured":"Montero-Iruzubieta J, Sanchez Hernandez MC, D\u00e1vila I, Leceta A. The importance of preventing and managing tear dysfunction syndrome in allergic conjunctivitis and how to tackle this problem. J Investig Allergol Clin Immunol. 2023;33(6):439\u201345.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"1150_CR26","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/ACI.0000000000000669","volume":"20","author":"N Kimchi","year":"2020","unstructured":"Kimchi N, Bielory L. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents. Curr Opin Allergy Clin Immunol. 2020;20(4):414\u201320.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"1150_CR27","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.2165\/00003495-199550060-00009","volume":"50","author":"S Noble","year":"1995","unstructured":"Noble S, McTavish D, Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Drugs. 1995;50(6):1032\u201349.","journal-title":"Drugs"},{"issue":"12","key":"1150_CR28","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1185\/030079904X5724","volume":"20","author":"MB Abelson","year":"2004","unstructured":"Abelson MB, Greiner JV. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Curr Med Res Opin. 2004;20(12):1953\u20138.","journal-title":"Curr Med Res Opin"},{"key":"1150_CR29","doi-asserted-by":"crossref","unstructured":"Discepola M, Deschenes J, Abelson M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl. 1999;(228):43\u20136.","DOI":"10.1111\/j.1600-0420.1999.tb01173.x"},{"key":"1150_CR30","doi-asserted-by":"crossref","unstructured":"Secchi A, Leonardi A, Discepola M, Deschenes J, Abelson MB. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand Suppl. 2000;(230):48\u201351.","DOI":"10.1034\/j.1600-0420.2000.078s230048.x"},{"issue":"4","key":"1150_CR31","first-page":"0","volume":"33","author":"PJ Gomes","year":"2022","unstructured":"Gomes PJ, Ciolino JB, Arranz P, Hernandez G, Fernandez N. Efficacy of once-daily ophthalmic bilastine for the treatment of allergic conjunctivitis: a dose-finding study. J Investig Allergol Clin Immunol. 2022;33(4):0.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1150_CR32","unstructured":"Multi-Center A. Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle. Clinical Trials.gov.\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01881113?term=cetirizine+0.24&draw=2&rank=3."},{"key":"1150_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/OPTH.S186092","volume":"13","author":"RP Malhotra","year":"2019","unstructured":"Malhotra RP, Meier E, Torkildsen G, Gomes PJ, Jasek MC. Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects. Clin Ophthalmol. 2019;13:403\u201313.","journal-title":"Clin Ophthalmol"},{"key":"1150_CR34","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.2147\/OPTH.S185835","volume":"12","author":"EJ Meier","year":"2018","unstructured":"Meier EJ, Torkildsen GL, Gomes PJ, Jasek MC. Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model. Clin Ophthalmol. 2018;12:2617\u201328.","journal-title":"Clin Ophthalmol"},{"key":"1150_CR35","doi-asserted-by":"crossref","unstructured":"Gomes PJ, Ciolino JB, Arranz P, Hern\u00e1ndez G, Fern\u00e1ndez N. Bilastine 0.6% preservative-free eye drops, a once-daily treatment for allergic conjunctivitis. J Investig Allergol Clin Immunol. 2023;0.","DOI":"10.18176\/jiaci.0894"},{"key":"1150_CR36","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2147\/OPTH.S398168","volume":"17","author":"P Kuna","year":"2023","unstructured":"Kuna P, Jutel M, Pulka G, Tokarski S, Arranz P, Hern\u00e1ndez G, et al. Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: an 8-Weeks phase III study. Clin Ophthalmol. 2023;17:735\u201346. The new once daily topical antihistamine for the treatment of ocular allergy that protects and hydrates ocular surface.","journal-title":"Clin Ophthalmol"},{"key":"1150_CR37","unstructured":"Clinical Trials. gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03231969; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03479307 [Last accessed: December, 2022]."},{"issue":"9","key":"1150_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1089\/jop.2022.0024","volume":"38","author":"I Torrens","year":"2022","unstructured":"Torrens I, Ganza \u00c1, Hern\u00e1ndez G, Gonzalo A, Zazpe A. Ocular biodistribution of once-daily 0.6% Bilastine Eye drops reveals highest levels in Conjunctiva up to 24\u00a0h postadministration. J Ocul Pharmacol Ther. 2022;38(9):617\u201325.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1150_CR39","doi-asserted-by":"crossref","unstructured":"Gomes PJ, Ciolino JB, Arranz P, Gonzalo A, Fern\u00e1ndez N, Hern\u00e1ndez G. Bilastine 0.6% preservative-free eye drops, an effective once-daily treatment to reduce signs and symptoms of allergic conjunctivitis: a pooled analysis of two randomized clinical trials. J Investig Allergol Clin Immunol. 2023;0.","DOI":"10.18176\/jiaci.0940"},{"issue":"2","key":"1150_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2500\/ar.2016.7.0158","volume":"7","author":"W Carr","year":"2016","unstructured":"Carr W, Schaeffer J, Donnenfeld E. Treating allergic conjunctivitis: a once-daily medication that provides 24-hour symptom relief. Allergy Rhinol (Providence). 2016;7(2):107\u201314.","journal-title":"Allergy Rhinol (Providence)"},{"key":"1150_CR41","doi-asserted-by":"publisher","first-page":"j4706","DOI":"10.1136\/bmj.j4706","volume":"359","author":"DS Patel","year":"2017","unstructured":"Patel DS, Arunakirinathan M, Stuart A, Angunawela R. Allergic eye disease. BMJ. 2017;359:j4706.","journal-title":"BMJ"},{"key":"1150_CR42","volume-title":"Middleton\u2019s allergy: principles and practice","author":"AW Burks","year":"2020","unstructured":"Burks AW, Holgate ST, O\u2019Hehir RE, Broide DH, Bacharier LB, Hershey GKK, et al. Middleton\u2019s allergy: principles and practice. Amsterdam: Elsevier; 2020."},{"issue":"5","key":"1150_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3109\/09273948.2016.1158282","volume":"25","author":"KW Kam","year":"2017","unstructured":"Kam KW, Chen LJ, Wat N, Young AL. Topical olopatadine in the treatment of allergic conjunctivitis: a systematic review and Meta-analysis. Ocul Immunol Inflamm. 2017;25(5):663\u201377.","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"1150_CR44","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.4103\/ijo.IJO_2112_18","volume":"67","author":"L Dudeja","year":"2019","unstructured":"Dudeja L, Janakiraman A, Dudeja I, Sane K, Babu M. Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis. Indian J Ophthalmol. 2019;67(9):1400\u20134.","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"1150_CR45","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/ijo.IJO_2083_20","volume":"69","author":"S Ayyappanavar","year":"2021","unstructured":"Ayyappanavar S, Sridhar S, Kumar K, Jayanthi CR, Gangasagara SB, Rathod BLS, et al. Comparative analysis of safety and efficacy of Alcaftadine 0.25%, olopatadine hydrochloride 0.2% and bepotastine besilate 1.5% in allergic conjunctivitis. Indian J Ophthalmol. 2021;69(2):257\u201361.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"1150_CR46","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1185\/030079904125004321","volume":"20","author":"A Leonardi","year":"2004","unstructured":"Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr Med Res Opin. 2004;20(8):1167\u201373.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1150_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jfo.2013.02.007","volume":"37","author":"B Mortemousque","year":"2014","unstructured":"Mortemousque B, Bourcier T, Khairallah M, Messaoud R, Brignole-Baudouin F, Renault D, et al. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis. J Fr Ophtalmol. 2014;37(1):1\u20138.","journal-title":"J Fr Ophtalmol"},{"key":"1150_CR48","unstructured":"ZABAK 0. 25\u00a0mg\/ml, eye drops, solution. Ketotifen. PACKAGE LEAFLET: INFORMATION FOR THE USER. https:\/\/file.wuxuwang.com\/hma\/FR_H_0411_001_FinalPL.pdf."},{"key":"1150_CR49","unstructured":"Olodon Free (Olopatadine 1\u00a0mg). POLPHARMA Polfa Warszawa Available at: S.A.\u00a0https:\/\/polpharma.pl\/wp-content\/uploads\/2020\/08\/73992_.pdf."},{"key":"1150_CR50","unstructured":"Tebarat. (Azelastine 0.5\u00a0mg\/ml eye drops solution in a single-dose package). Tecnical data sheet. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/77005\/FT_77005.html."},{"issue":"1","key":"1150_CR51","first-page":"P94","volume":"126","author":"DM Varu","year":"2019","unstructured":"Varu DM, Rhee MK, Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, et al. Conjunctivitis Preferred Pract Pattern\u00ae Ophthalmol. 2019;126(1):P94\u2013169.","journal-title":"Conjunctivitis Preferred Pract Pattern\u00ae Ophthalmol"},{"issue":"4","key":"1150_CR52","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2500\/aap.2009.30.3238","volume":"30","author":"R Anolik","year":"2009","unstructured":"Anolik R, Pearlman D, Teper A, Gates D. Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc. 2009;30(4):406\u201312.","journal-title":"Allergy Asthma Proc."},{"issue":"2","key":"1150_CR53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41433-021-01668-x","volume":"36","author":"MH Goldstein","year":"2022","unstructured":"Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye (Lond). 2022;36(2):361\u20138.","journal-title":"Eye (Lond)"},{"key":"1150_CR54","unstructured":"Zaditen 0. 25\u00a0mg\/ml eye drops in solution in single-dose packs. Ketotifen. Technical data sheet.\u00a0https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/63616\/FichaTecnica_63616.html."},{"key":"1150_CR55","unstructured":"Azelastin-COMOD 0. 5\u00a0mg\/ml eye drops, solution. Azelastine hydrochloride. Product information. https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiZ6LO1kfL_AhVtUaQEHcEfBZMQFnoECCEQAQ&url=https%3A%2F%2Fmri.cts-mrp.eu%2Fportal%2Fv1%2Fodata%2FDocument(4483a37c-da29-eb11-80eb-0050569c593a)%2FDownload&usg=AOvVaw2zumjX3hX9QO9AEtXI-DIy&opi=89978449."},{"key":"1150_CR56","doi-asserted-by":"crossref","unstructured":"Labetoulle M, Benitez-Del-castillo JM, Barabino S, Vanrell RH, Daull P, Garrigue JS et al. Artificial tears: Biological Role of their ingredients in the management of Dry Eye Disease. Int J Mol Sci. 2022;23(5).","DOI":"10.3390\/ijms23052434"},{"issue":"6","key":"1150_CR57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/ICL.0000000000000284","volume":"43","author":"A La L\u00f3pez-De","year":"2017","unstructured":"La L\u00f3pez-De A, Pinto-Fraga J, Bl\u00e1zquez Arauzo F, Rodr\u00edguez RU, Gonz\u00e1lez-Garc\u00eda MJ. Safety and efficacy of an artificial tear containing 0.3% hyaluronic acid in the management of moderate-to-severe dry eye disease. Eye Contact Lens. 2017;43(6):383\u20138.","journal-title":"Eye Contact Lens"},{"key":"1150_CR58","doi-asserted-by":"crossref","unstructured":"Aragona P, Simmons PA, Wang H, Wang T. Physicochemical properties of hyaluronic acid\u2013based lubricant eye drops. Translational Vis Sci Technol. 2019;8(6).","DOI":"10.1167\/tvst.8.6.2"},{"issue":"7","key":"1150_CR59","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/02713683.2020.1849733","volume":"46","author":"S Belalc\u00e1zar-Rey","year":"2021","unstructured":"Belalc\u00e1zar-Rey S, S\u00e1nchez Huerta V, Ochoa-Tabares JC, Altamirano Vallejo S, Soto-G\u00f3mez A, Su\u00e1rez-Velasco R, et al. Efficacy and safety of Sodium Hyaluronate\/chondroitin Sulfate Preservative-free Ophthalmic solution in the treatment of Dry Eye: a clinical trial. Curr Eye Res. 2021;46(7):919\u201329.","journal-title":"Curr Eye Res"},{"key":"1150_CR60","doi-asserted-by":"crossref","unstructured":"Huerta \u00c1ngeles G, Ne\u0161porov\u00e1 K. Hyaluronan and its derivatives for ophthalmology: recent advances and future perspectives. Carbohydr Polym. 2021;259.","DOI":"10.1016\/j.carbpol.2021.117697"},{"key":"1150_CR61","unstructured":"Arana E. The new once daily multidose preservative free 0.6% bilastine eye drop formulation containing sodium hyaluronate protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study. EAACI 2022 #000949 Abstract Prague. Czech Republic; July 2022."},{"issue":"6","key":"1150_CR62","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/cea.12536","volume":"45","author":"A Leonardi","year":"2015","unstructured":"Leonardi A, Piliego F, Castegnaro A, Lazzarini D, La Gloria Valerio A, Mattana P, et al. Allergic conjunctivitis: a cross-sectional study. Clin Exp Allergy. 2015;45(6):1118\u201325.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"1150_CR63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijpharm.2016.06.135","volume":"511","author":"JJ Hakkarainen","year":"2016","unstructured":"Hakkarainen JJ, Reinisalo M, Ragauskas S, Sepp\u00e4nen A, Kaja S, Kalesnykas G. Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. Int J Pharm. 2016;511(1):73\u20138.","journal-title":"Int J Pharm"},{"key":"1150_CR64","unstructured":"Drynol 6\u00a0mg. \/mL eye drops, solution. Health Products Regulatory Authority. 22 July 2022. Summary of Product Characteristic. https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/Licence_PA0865-018-005_22072022145400.pdf."},{"key":"1150_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2018.01.011","volume":"188","author":"KH Na","year":"2018","unstructured":"Na KH, Yoo C, Park JH, Kim YY. Eye Drop Dispenser type and medication possession ratio in patients with Glaucoma: single-Use Containers Versus multiple-use bottles. Am J Ophthalmol. 2018;188:9\u201318.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1150_CR66","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1177\/1120672120919342","volume":"31","author":"P Denis","year":"2021","unstructured":"Denis P, Duch S, Chen E, Klyve P, Skov J, Puska P, et al. European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment. Eur J Ophthalmol. 2021;31(3):1056\u201363.","journal-title":"Eur J Ophthalmol"},{"key":"1150_CR67","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.2147\/PPA.S264926","volume":"15","author":"I Tapply","year":"2021","unstructured":"Tapply I, Broadway DC. Improving adherence to Topical Medication in patients with Glaucoma. Patient Prefer Adherence. 2021;15:1477\u201389.","journal-title":"Patient Prefer Adherence"},{"issue":"11 Suppl","key":"1150_CR68","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.ophtha.2009.06.024","volume":"116","author":"JC Tsai","year":"2009","unstructured":"Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11 Suppl):S30\u20136.","journal-title":"Ophthalmology"},{"issue":"4","key":"1150_CR69","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144(4):533\u201340.","journal-title":"Am J Ophthalmol"},{"key":"1150_CR70","unstructured":"ZERVIATE\u2122(cetirizine ophthalmic. solution) 0.24%, for topical ophthalmic use. Product information. https:\/\/myzerviate.com\/files\/Zerviate_PI.pdf."},{"key":"1150_CR71","unstructured":"EMADINE 0. 5\u00a0mg\/ml, eye drops, solution. Emadine. European public assessment report. Product Infomation. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emadine-epar-product-information_en.pdf."},{"key":"1150_CR72","unstructured":"Bilina 0. 5\u00a0mg\/ml eye drops suspension. Levocabastine. Technical data sheet. https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/60917\/60917_ft.pdf."},{"key":"1150_CR73","unstructured":"LASTACAFT\u2122 (alcaftadine ophthalmic. solution 0.25%). Product information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022134s000lbl.pdf."},{"key":"1150_CR74","unstructured":"Azelastine. hydrochloride 0.5\u00a0mg\/ml Eye drops, solution. Product information. https:\/\/www.medicines.org.uk\/emc\/product\/11152\/smpc#gref."},{"key":"1150_CR75","unstructured":"Azelastina POS. 0,5\u00a0mg\/ml. Brill Pharma. Azelastina hidrocloruro al 0,05% (0,50\u00a0mg\/ml). Technical data sheet. Available in: https:\/\/www.brillpharma.com\/wp-content\/uploads\/2020\/12\/FT_81144.pdf."},{"key":"1150_CR76","unstructured":"Bepreve (bepotastine besilate ophthalmic solution) 1.5%. BEPREVE. Tampa, FL: Bausch & Lomb Incorporated. 2019 https:\/\/www.bausch.com\/globalassets\/pdf\/packageinserts\/pharma\/bepreve-prescribing-info.pdf."},{"key":"1150_CR77","unstructured":"Relestat. 0.5\u00a0mg\/ml, eye drops, solution. Epinastine. Product information. https:\/\/www.medicines.org.uk\/emc\/product\/29."},{"key":"1150_CR78","unstructured":"Zaditen 0. 25\u00a0mg\/ml eye drops solution. Ketotifen. Technical data sheet. https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/63619\/FT_63619.pdf."},{"key":"1150_CR79","unstructured":"Collirio KETOFTIL. soluzione 0.05% (Ketotifen)DATASHEET. Available in: https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_000533_029278_FI.pdf&sys=m0b1l3."},{"key":"1150_CR80","unstructured":"Opatanol 1\u00a0mg. \/ml eye drops, solution. Olopatadine. European public assessment report. Product Infomation. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opatanol-epar-product-information_en.pdf."},{"key":"1150_CR81","unstructured":"PATADAY\u2122 (olopatadine hydrochloride. ophthalmic solution) 0.2%. Product information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021545s013lbl.pdf."},{"issue":"7","key":"1150_CR82","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1007\/s12325-021-01801-y","volume":"38","author":"D Ochoa","year":"2021","unstructured":"Ochoa D, Roman M, Belmonte C, Martin-Vilchez S, Mejia-Abril G, Abad-Santos F, et al. Pharmacokinetics and safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation. Adv Ther. 2021;38(7):4070\u201381.","journal-title":"Adv Ther"},{"key":"1150_CR83","unstructured":"Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis. ClinicalTrials Gov Available in: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00133627."},{"issue":"1 Pt 1","key":"1150_CR84","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0091-6749(93)90040-M","volume":"92","author":"P S\u00f8hoel","year":"1993","unstructured":"S\u00f8hoel P, Freng BA, Kramer J, Poppe S, Rebo R, Korsrud FR, et al. Topical levocabastine compared with orally administered terfenadine for the prophylaxis and treatment of seasonal rhinoconjunctivitis. J Allergy Clin Immunol. 1993;92(1 Pt 1):73\u201381.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1150_CR85","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/112067219800800402","volume":"8","author":"C Richard","year":"1998","unstructured":"Richard C, Trinquand C, Bloch-Michel E. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group. Eur J Ophthalmol. 1998;8(4):207\u201316.","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"1150_CR86","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jfo.2011.08.016","volume":"35","author":"C Allaire","year":"2012","unstructured":"Allaire C, Siou-Mermet R, Bassols A. [Safety and efficacy of a new preservative-free levocabastine ophthalmic solution (Levofree\u00ae) using the conjunctival provocation test]. J Fr Ophtalmol. 2012;35(7):491\u20138.","journal-title":"J Fr Ophtalmol"},{"issue":"4","key":"1150_CR87","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1080\/09273948.2018.1432764","volume":"27","author":"H Nakatani","year":"2019","unstructured":"Nakatani H, Gomes P, Bradford R, Guo Q, Safyan E, Hollander DA. Alcaftadine 0.25% versus olopatadine 0.1% in preventing Cedar Pollen allergic conjunctivitis in Japan: a randomized study. Ocul Immunol Inflamm. 2019;27(4):622\u201331.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"1150_CR88","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1365-2222.1997.tb00691.x","volume":"27","author":"G Ciprandi","year":"1997","unstructured":"Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy. 1997;27(2):182\u201391.","journal-title":"Clin Exp Allergy"},{"issue":"6 Pt 1","key":"1150_CR89","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/S0091-6749(96)80196-5","volume":"98","author":"G Ciprandi","year":"1996","unstructured":"Ciprandi G, Pronzato C, Passalacqua G, Ricca V, Gr\u00f6gen J, Mela GS, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol. 1996;98(6 Pt 1):1088\u201396.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1150_CR90","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1185\/030079903125001794","volume":"19","author":"GW Canonica","year":"2003","unstructured":"Canonica GW, Ciprandi G, Petzold U, Kolb C, Ellers-Lenz B, Hermann R. Topical azelastine in perennial allergic conjunctivitis. Curr Med Res Opin. 2003;19(4):321\u20139.","journal-title":"Curr Med Res Opin"},{"key":"1150_CR91","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/OPTH.S5223","volume":"3","author":"AB Epstein","year":"2009","unstructured":"Epstein AB, Van Hoven PT, Kaufman A, Carr WW. Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clin Ophthalmol. 2009;3:329\u201336.","journal-title":"Clin Ophthalmol"},{"key":"1150_CR92","unstructured":"Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis. ClinivalTrials.gov. Available in: [https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00586664?term=Bepotastine+besilate&draw=2&rank=20]."},{"issue":"16","key":"1150_CR93","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1517\/14656566.2015.1085511","volume":"16","author":"K Okubo","year":"2015","unstructured":"Okubo K, Ichimura M, Koyama T, Susuta Y, Izaki H. Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis. Expert Opin Pharmacother. 2015;16(16):2395\u2013408.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1150_CR94","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0149-2918(04)90004-5","volume":"26","author":"MB Abelson","year":"2004","unstructured":"Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther. 2004;26(1):35\u201347.","journal-title":"Clin Ther"},{"issue":"1","key":"1150_CR95","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0149-2918(04)90003-3","volume":"26","author":"SM Whitcup","year":"2004","unstructured":"Whitcup SM, Bradford R, Lue J, Schiffman RM, Abelson MB. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther. 2004;26(1):29\u201334.","journal-title":"Clin Ther"},{"issue":"4","key":"1150_CR96","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1185\/030079903125001785","volume":"19","author":"IG James","year":"2003","unstructured":"James IG, Campbell LM, Harrison JM, Fell PJ, Ellers-Lenz B, Petzold U. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin. 2003;19(4):313\u201320.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"1150_CR97","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/S0149-2918(08)80050-1","volume":"30","author":"GL Torkildsen","year":"2008","unstructured":"Torkildsen GL, Ousler GW 3rd, Gomes P. Ocular comfort and drying effects of three topical antihistamine\/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study. Clin Ther. 2008;30(7):1264\u201371.","journal-title":"Clin Ther"},{"issue":"8","key":"1150_CR98","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1080\/09273948.2018.1530363","volume":"27","author":"A Leonardi","year":"2019","unstructured":"Leonardi A, Capobianco D, Benedetti N, Capobianco A, Cavarzeran F, Scalora T, et al. Efficacy and tolerability of Ketotifen in the treatment of Seasonal allergic conjunctivitis: comparison between Ketotifen 0.025% and 0.05% Eye drops. Ocul Immunol Inflamm. 2019;27(8):1352\u20136.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"1150_CR99","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1755-3768.2008.01265.x","volume":"87","author":"M Borazan","year":"2009","unstructured":"Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol. 2009;87(5):549\u201354.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"1150_CR100","doi-asserted-by":"publisher","first-page":"16","DOI":"10.51253\/pafmj.v72i1.6324","volume":"72","author":"FU Abidin","year":"2022","unstructured":"Abidin FU, Sarfraz MH, Javaid H, Khan A, Khan S, Javaid H. Therapeutic efficacy of topical olopatadine 0.1% Versus Ketotifen Fumarate in allergic conjunctivitis. Pak Armed Forces Med J. 2022;72(1):16\u20139.","journal-title":"Pak Armed Forces Med J"},{"issue":"230","key":"1150_CR101","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1034\/j.1600-0420.2000.078s230052.x","volume":"78","author":"AJ Aguilar","year":"2000","unstructured":"Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand Suppl. 2000;78(230):52\u20135.","journal-title":"Acta Ophthalmol Scand Suppl"},{"issue":"1","key":"1150_CR102","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3109\/02713683.2013.827213","volume":"39","author":"T Celik","year":"2014","unstructured":"Celik T, Turkoglu EB. Comparative evaluation of olopatadine 0.01% combined fluorometholone 0.1% treatment versus olopatadine 0.01% combined ketorolac 0.4% treatment in patients with acute seasonal allergic conjunctivitis. Curr Eye Res. 2014;39(1):42\u20136.","journal-title":"Curr Eye Res"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01150-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-024-01150-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01150-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T05:17:56Z","timestamp":1720502276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-024-01150-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":102,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1007\/s11882-024-01150-0","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"assertion":[{"value":"13 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"AL: has received fees as a speaker, writing, scientific advisor from FAES Farma, Santen, Fidia and Thea. LQ declares that he has no conflict of interest. IJP has received fees as a speaker, medical writer, lecturer and\/or scientific advisor from FAES Farma, Sanofi, Novartis, GSK, Abbvie, and Organon; support for attending meetings from FAES Farma, Sanofi, Novartis, and GSK; and as a member of data monitoring committees from Roxall. JMBdC has received fees as a speaker, writing, scientific advisor from Alcon, Faes, Fidia, Santen, Sifi, Thea. FJSL has received fees as a speaker, writing, scientific advisor from Gebro Pharma, Chiesi and FAES Farma. RA has received fees as a speaker, writing, scientific advisor, manuscript writing or educational event and support for attending meetings from Allergy Therapeutics, Glaxo Smith Kline, HAL Allergy, Lofarma, Malesci, Novartis, Sanofi, Smart Practice and Thermo Fisher. JM has received support for attending meetings from Thea Lab, Brill Lab, and Santen. JMLL declares that he has no conflict of interest. EGM declares that she has no conflict of interest. RA has been a speaker, writer or scientific advisor for Novartis, GSK, Sanofi Genzyme, ThermoFisher, Lofarma, Smart Practice, HAL Allergy, Allergy Therapeutics, ALK. AG has received fees as a speaker, writing, scientific advisor, manuscript writing or educational event and support for attending meetings for Adamed, Alcon, Bausch, FAES Farma Menarini, Mediton, Novartis, Polpharma, Polfa Warszawa and Sanofi. PK has received fees for speaking, writing, scientific consultancy, manuscript writing and participation in educational events, and support for attending meetings for Adamed, AstraZeneca, Boehringer Ingelheim, GSK, Celon Pharma, Chiesi, Berlin Chemie Menarini, Novartis, Sanofi, Teva , Polpharma, Glenmark.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"AL: has received fees as a speaker, writing, scientific advisor from FAES Farma, Santen, Fidia and TheaLQ declares that he has no conflict of interest.IJP has received fees as a speaker, medical writer, lecturer and\/or scientific advisor from FAES Farma, Sanofi, Novartis, GSK, Abbvie, and Organon; support for attending meetings from FAES Farma, Sanofi, Novartis, and GSK; and as a member of data monitoring committees from Roxall. JMBdC has received fees as a speaker, writing, scientific advisor from Alcon, Faes, Fidia, Santen, Sifi, Thea.FJSL has received fees as a speaker, writing, scientific advisor from Gebro Pharma, Chiesi and FAES Farma.RA has received fees as a speaker, writing, scientific advisor, manuscript writing or educational event and support for attending meetings from Allergy Therapeutics, Glaxo Smith Kline, HAL Allergy, Lofarma, Malesci, Novartis, Sanofi, Smart Practice and Thermo Fisher.JM has received support for attending meetings from Thea Lab, Brill Lab, and Santen.JMLL declares that he has no conflict of interest.EGM declares that she has no conflict of interestRA has been a speaker, writer or scientific advisor for Novartis, GSK, Sanofi Genzyme, ThermoFisher, Lofarma, Smart Practice, HAL Allergy, Allergy Therapeutics, ALKAG has received fees as a speaker, writing, scientific advisor, manuscript writing or educational event and support for attending meetings for Adamed, Alcon, Bausch, FAES Farma Menarini, Mediton, Novartis, Polpharma, Polfa Warszawa and Sanofi.PK has received fees for speaking, writing, scientific consultancy, manuscript writing and participation in educational events, and support for attending meetings for Adamed, AstraZeneca, Boehringer Ingelheim, GSK, Celon Pharma, Chiesi, Berlin Chemie Menarini, Novartis, Sanofi, Teva , Polpharma, Glenmark.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}